• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

byKathleen Lau
January 14, 2021
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

Active surveillance strategies to improve rates of inferior vena cava filter retrieval

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

Tags: blood cancerbortezomibcancerchemotherapydexamethasoneelotuzumabhematologyhigh-risk multiple myelomaimmunomodulator therapyimmunomodulatorsinductionlenalidomidemaintenanceMMmotor neuropathymultiple myelomamyelomaneuropathyoncologypfsphase 2 trialprogression-free survivalproteasome inhibitorrandomisedrandomised trialRVdsensory neuropathy
Previous Post

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

Next Post

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

RelatedReports

Endocrinology

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

March 24, 2023
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Cardiology

Active surveillance strategies to improve rates of inferior vena cava filter retrieval

March 22, 2023
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

March 21, 2023
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

March 20, 2023
Next Post
Prescription of antibiotics for acute respiratory infections increasing

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

Novel coronavirus identified from patients with pneumonia in Wuhan, China

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options